FDA Drug Application Rejections: CRL Statistics 2020-2025

VelSafe Insights

FDA Drug Application Rejections: 40+ Statistics from 291 Published CRLs

In July and September 2025, the FDA published 291 Complete Response Letters covering 2020 to 2025 in an act described as radical transparency. For the first time, the drug development industry can examine specific deficiency patterns across hundreds of non-approvals. The data reveals that 74% of rejections involved quality or manufacturing issues, 56% cited facility inspection failures, and 48% of CRLs flagged both safety and efficacy deficiencies simultaneously. This article compiles the key statistics and what they mean for regulatory strategy.

291 CRLs Analyzed

CMC and Manufacturing Failures

Safety and Efficacy Deficiencies

Approval Rates 2020-2025

291

Complete Response Letters published by the FDA across two 2025 releases covering 2020-2025

FDA / Syner-G, 2025

74%

of the 202 CRLs from 2020-2024 cited quality or manufacturing issues as a deficiency

Pharma Manufacturing, 2025

37%

of BLAs and NDAs submitted during the 2018-2022 PDUFA cycle received a Complete Response Letter

Avalere Health / Pharmacy Times, 2025

A Complete Response Letter is not the end of a drug application. It is the FDA telling a sponsor exactly what is wrong. For most of the FDA’s history, those specific reasons stayed private – shared with the applicant and no one else. That changed in July 2025, when the FDA published 202 CRLs from 2020 to 2024, and again in September 2025, when 89 more were added covering 2024 and 2025. For the first time, 291 letters describing the specific deficiencies behind hundreds of non-approvals are publicly accessible.

What the data shows is both instructive and sobering. Manufacturing and facility failures dominate. Clinical deficiencies cluster in predictable places – study design, non-U.S. populations, inadequate control arms. And 48% of letters cite both safety and efficacy problems simultaneously, suggesting that the issues rarely arrive in isolation. Below we have compiled 40+ statistics drawn from FDA records, independent CRL analyses, and regulatory intelligence sources to give drug developers and safety professionals the clearest picture yet of why applications fail.

Editor's Choice: Key FDA CRL Statistics

56%

of the 89 CRLs issued between January 2024 and January 2025 contained facility inspection-related approvability issues – the single largest deficiency category. (The FDA Group, September 2025)

74%

of 202 CRLs issued 2020-2024 cited quality or manufacturing deficiencies, including problems with processes, facility inspections, or CMC data. (Pharma Manufacturing, 2025)

48%

of CRLs cited deficiencies in both safety and efficacy domains simultaneously – the co-occurrence pattern that changes how developers should frame submission risk. (Applied Clinical Trials, 2025)

85%

of FDA concerns went undisclosed in sponsor public announcements about non-approvals, per a 2015 internal FDA analysis that helped drive the 2025 transparency initiative. (BMJ cross-sectional study)

70%

of CRLs were issued to small or mid-sized sponsors, underscoring the disproportionate impact of manufacturing and regulatory capacity gaps on smaller organizations. (Auria Compliance, 2025)

30%+

of the 89 CRLs from 2024-2025 cited clinical or clinical/statistical failures – inadequate trial design, insufficient efficacy data, or safety profile concerns. (The FDA Group, 2025)

1. The FDA Transparency Shift: What 291 Published CRLs Represent

CRL Publication Timeline: From Decades of Secrecy to Real-Time Disclosure

Pre-2025

CRLs shared only with product sponsors. Sponsors under no obligation to disclose FDA concerns publicly. 85% of FDA issues went unreported in company announcements.

July 2025

FDA publishes 202 CRLs from 2020-2024 via open.fda.gov – only those where the drug was later approved. First centralized database of past CRLs in FDA history.

Sept 2025

FDA releases 89 additional CRLs covering 2024-2025, including letters to Replimune, Capricor Therapeutics, Lykos Therapeutics, Rocket Pharmaceuticals, and Ultragenyx.

Going Forward

FDA announces real-time CRL release policy – letters to be published promptly after issuance, covering both approved and unapproved applications.

Sources: STAT News (2025); BioSpace (2025); open.fda.gov (2025)

The FDA published 202 Complete Response Letters from 2020-2024 on July 10, 2025, describing it as an act of radical transparency – the first centralized public database of CRLs in the agency’s history. (FDA press announcement, July 2025)
A second batch of 89 CRLs from 2024-2025 was released on September 4, 2025, alongside an announcement that CRLs would be published promptly in real time going forward. (STAT News, September 2025)
The July 2025 batch covered only since-approved applications. The September batch included letters for unapproved drugs such as Lykos Therapeutics’ MDMA therapy for PTSD, rejected in August 2024. (BioSpace, September 2025)
37% of BLAs and NDAs submitted during the 2018-2022 PDUFA cycle received a Complete Response Letter – and a CRL does not guarantee future approval upon resubmission. (Avalere Health, cited in Pharmacy Times, 2025)
Several companies received multiple CRLs across the 2020-2024 period, including Alvotech, Azurity Pharmaceuticals, Celltrion, Coherus BioSciences, Dr. Reddy’s Laboratories, Eli Lilly, Pfizer, Sun Pharma, and Teva Pharmaceuticals. (Pharma Manufacturing, 2025)

2. Manufacturing and CMC Deficiencies: The Dominant CRL Category

Quality/Manufacturing (2020-2024)

74% (150/202 CRLs)

Facility Inspections (2024-2025)

56% (50/89 CRLs)

Manufacturing/CMC (Compliance Insight)

~44%

CRLs to Small/Mid Sponsors

~70%

Sources: Pharma Manufacturing (2025); The FDA Group (2025); Compliance Insight (2025); Auria Compliance (2025)

Out of 202 CRLs issued from 2020-2024, 150 (74%) involved quality or manufacturing issues, including problems with manufacturing processes, facility inspections, and CMC data – the dominant category across the entire dataset. (Pharma Manufacturing, 2025)
Analysis of 89 CRLs from 2024-2025 found that 56% (50 letters) cited facility inspection-related approvability issues, making it the single most common deficiency in that cohort. (The FDA Group, September 2025)
74% of CRLs from 2020-2024 cited CMC deficiencies, with the FDA increasingly inspecting coherence between the submitted CMC package and actual commercial readiness – a gap often created by CDMO reliance. (Pharma Tech, 2025)
CMC deficiency sub-categories include process validation failures, analytical method gaps, stability data deficiencies, container closure concerns, and drug substance impurity profile issues – none are discovered only late in development, yet they consistently surface at submission. (Assyro AI, 2026)
In 2024, an estimated 85% of small biopharma companies outsourced API production and 77% outsourced finished dose manufacturing – creating a structural dependency on CDMOs whose inspection readiness directly affects CRL risk. (William Blair analysis, cited in Outsourced Pharma, 2025)
Manufacturing-related issues were not evenly distributed across product types – injectables, biologics, and complex modalities received the highest proportion of CMC-related citations. (Outsourced Pharma AI analysis, 2025)

3. Clinical and Efficacy Deficiencies: Statistics on Trial Design Failures

Inadequate Control Arms

Trial design that fails to demonstrate superiority or non-inferiority relative to an appropriate comparator. A recurring CRL driver across oncology and rare disease applications.

Non-U.S. Population Studies

Trials conducted exclusively in non-U.S. populations without bridging data. The sintilimab case established this as a clear FDA rejection trigger.

FDA Guidance Misalignment

Lack of alignment with FDA guidance documents during study design. Issues that could have been identified in Type B meetings frequently appear in CRLs instead.

Safety Profile Concerns

Unreported adverse events, abuse potential during treatment, or inconsistent safety data across sites. The Lykos MDMA rejection specifically cited unreported safety events at two clinical sites.

Over 30% of the 89 CRLs from 2024-2025 included clinical or clinical/statistical failures – inadequate efficacy data, poor study design, or safety profile concerns requiring additional trials. (The FDA Group, September 2025)
44% of CRLs cited clinical evidence gaps according to Compliance Insight’s analysis of the 2020-2024 dataset – including insufficient efficacy data, poor study design, and safety concerns. (Compliance Insight, 2025)
48% of CRLs cited deficiencies in both safety and efficacy domains simultaneously – the co-occurrence rate that signals multi-dimensional submission risk rather than isolated failures. (Applied Clinical Trials, 2025)
CRLs frequently flagged issues not tied to clinical data itself but to how the study was designed or executed – inadequate control arms, non-U.S. population exclusivity, and failure to align with FDA guidance documents. (Auria Compliance, 2025)
The Lykos Therapeutics MDMA rejection letter (August 2024) specifically cited unreported safety events at two clinical sites and concerns about abuse potential during the in-patient treatment process – an example of safety execution failures driving clinical CRLs. (BioSpace, September 2025)
Over half of CRLs involved more than one major category of deficiency, requiring cross-functional remediation across clinical, CMC, labeling, and regulatory affairs teams simultaneously. (Auria Compliance, 2025)

4. The Transparency Gap: How Sponsors Previously Disclosed CRL Content

85%

of FDA concerns went undisclosed in sponsor announcements (2015 internal FDA analysis)

BMJ cross-sectional study

202

CRLs published in the first July 2025 batch, the largest single disclosure of rejection reasons in FDA history

FDA, July 2025

of the 202 CRLs in the July batch were for oncology-related treatments and products

OncLive, 2025

A 2015 internal FDA analysis found that sponsors failed to disclose 85% of the agency’s concerns when announcing non-approvals publicly – a transparency gap the 2025 CRL releases were specifically designed to address. (BMJ cross-sectional study, cited in multiple analyses)
Sponsors are under no legal obligation to reveal the full content of a CRL – many issue short press releases stating no safety concerns were raised and provide no further detail, regardless of the actual CRL content. (BioSpace, 2025)
The July 2025 batch was limited to drugs that were subsequently approved – meaning the published CRLs represent the resolvable end of the rejection spectrum, not the full range of application failures. (BioPharma Dive, 2025)
Many of the published CRLs were heavily redacted to remove trade secrets and confidential commercial information – particularly in CMC sections, where the most proprietary manufacturing details appear. (BioSpace, September 2025)
32 of the 202 letters in the July batch were issued in response to oncology applications, reflecting the high volume of cancer drug submissions relative to other therapeutic areas. (OncLive, 2025)

5. FDA Drug Approval Rate Statistics: Context for the CRL Dataset

FDA Novel Drug Approvals by Year (Small Molecules and Biologics)

2020

2021

2022

2023

2024

2025

10-year rolling average: ~46.5 approvals/year. Sources: FDA CDER; PMC (2025); BLA Regulatory (2025)

The FDA approved 50 novel drugs in 2024, with 48% classified as first-in-class, 52% targeting rare diseases, and 66% using one or more expedited review programs. (Pharmacy Times, 2025)
The 10-year rolling average for FDA novel drug approvals is approximately 46.5 per year, with 2024 matching that average and 2025 coming in slightly below at 46. (BLA Regulatory, 2025)
In 2024, 74% of approvals (37 out of 50) cleared on the first review cycle, and 68% (34 out of 50) were approved in the U.S. before any other global regulator. (BLA Regulatory, 2025)
The FDA achieved a 94% PDUFA goal date compliance rate in 2024 – meaning the review timeline challenge for most sponsors is the quality of submissions, not the speed of FDA review. (BLA Regulatory, 2025)
The 2022 dip to 37 approvals represents the lowest point of the decade – a year in which CRL issuance remained consistent, suggesting that external factors (pandemic inspection backlog, supply chain disruptions) contributed to the reduction rather than a change in FDA standards. (PMC analysis, 2025)
Biologics represented 32% of 2024 drug approvals (16 out of 50), consistent with the 10-year trend of approximately one-third of approvals being biologics. The proportion dropped slightly in 2025 to 26%. (PMC, 2025)

6. Labeling, Bioequivalence, and Data Integrity Deficiencies

Labeling (~23%)

Facility Inspection (20%)

Bioequivalence (ANDAs)

Data Integrity

Quality System Gaps

Process Validation

Source: Compliance Insight (2025) – CRL deficiency categories from the 2020-2024 dataset

Labeling deficiencies appeared in approximately 23% of CRLs – including missing or misleading usage instructions, safety warnings, and inconsistencies – most commonly in ANDA (generic drug) applications. (Compliance Insight, 2025)
Facility inspection failures appeared in 20% of CRLs in the Compliance Insight analysis, flagging GMP site issues including uncontrolled processes, document gaps, and hygiene findings. (Compliance Insight, 2025)
Data integrity and electronic records issues – unreliable data, missing audit trails, or Part 11 non-compliance – appeared as a distinct CRL category independent of CMC failures, suggesting that documentation practices themselves are evaluated separately from manufacturing quality. (Compliance Insight, 2025)
Process validation issues – inadequate process qualification or failure to demonstrate ongoing control of critical process parameters – represent a technically solvable but resource-intensive CRL category requiring additional manufacturing runs and new stability studies. (Assyro AI, 2026)
All 27 CRLs from the September 2025 batch cited facility inspection deficiencies, with four specifically tied to inspection timing challenges – three from COVID-related travel restrictions and one from a late-included manufacturing site. (Syner-G, 2026)

7. Expedited Pathways: How Fast-Track and Breakthrough Designations Interact with CRL Risk

66%

of 2024 novel drug approvals used one or more expedited review programs

Pharmacy Times, 2025

52%

of 2024 approvals received orphan drug designation targeting rare diseases

Pharmacy Times, 2025

57%

of the 897 novel drugs approved 2000-2024 classified as specialty drugs by major PBMs

PMC / JAMA, 2025

66% of 2024 novel drug approvals used at least one expedited program, including fast track designation, breakthrough therapy designation, priority review, or accelerated approval – reflecting the FDA’s preference for moving transformative therapies forward quickly. (Pharmacy Times, 2025)
Expedited designation does not eliminate CRL risk. The published letters show that breakthrough-designated drugs also received CRLs, typically for CMC or facility readiness gaps discovered at the manufacturing stage rather than during clinical review. (Auria Compliance, 2025)
The FDA’s priority review program targets a 6-month review window compared to the standard 10 months – meaning sponsors using priority review have even less time to address manufacturing and CMC readiness before the PDUFA date. (Pharmacy Times, 2025)
Since 2012, specialty drugs have accounted for more than half of FDA drug approvals in every single year, growing at approximately 3% per year since 2000 – a trend with direct implications for CMC complexity and CRL risk. (PMC, 2025)
The 10-year average of 46.5 novel approvals annually means the baseline CRL rate of 37% of submitted applications translates to a substantial volume of rejection letters in any given year – now publicly accessible for the first time. (BLA Regulatory, 2025; Avalere Health)

8. What CRL Data Means for Drug Development and Regulatory Strategy

For Manufacturers Relying on CDMOs

With 74% of CRLs tied to manufacturing deficiencies and 85% of small biopharma outsourcing API production, CDMO inspection readiness is now a direct CRL risk factor. Sponsors bear full regulatory responsibility regardless of CDMO performance.

For Clinical Development Teams

The 48% co-occurrence rate for safety and efficacy deficiencies suggests that sponsors presenting borderline efficacy data also face heightened safety scrutiny. Weak efficacy does not get resolved by clean safety data alone.

For Regulatory Affairs Teams

The 291 published CRLs are now a searchable repository of specific deficiency language. Organizations that read these systematically – not selectively – will identify patterns in FDA language that can be compared against their own submissions.

The FDA’s stated goal in publishing CRLs was to allow drug developers to avoid repeating deficiencies that other sponsors have already addressed – the 291 letters are an industry-wide learning resource, not just a transparency gesture. (Applied Clinical Trials, 2025)
Approximately 75% of CRLs concerned specific manufacturing challenges according to AI-generated review of the published letters, confirming that manufacturing readiness is the primary risk category across the entire dataset. (Outsourced Pharma, 2025)
The CMC coherence gap – where the submitted package does not match the actual state of commercial readiness – is increasingly what FDA inspectors evaluate during pre-approval inspections, beyond standard GMP compliance. (Pharma Tech, 2025)
The real-time CRL disclosure policy announced in September 2025 means future rejections will be visible to competitors almost immediately – creating both risk and intelligence opportunity for sponsors monitoring competitor application status. (STAT News, 2025)

Key Takeaways for Drug Development and Regulatory Safety Professionals

Manufacturing readiness is the primary CRL risk

74% of 202 CRLs from 2020-2024 cited quality or manufacturing issues. For organizations relying on CDMOs, this means CDMO inspection readiness is now a first-order regulatory risk – and the sponsor bears full accountability for CDMO deficiencies.

Safety and efficacy failures rarely arrive alone

48% of CRLs cited deficiencies in both domains simultaneously. Sponsors planning to address safety concerns separately from efficacy concerns after a CRL need to treat them as a linked problem, not an independent one.

291 letters are a searchable learning resource

The FDA’s explicit goal was to reduce repeated submission errors. Organizations that systematically mine the published CRLs for deficiency language relevant to their own product type, manufacturing setup, and therapeutic area will have a material advantage over those who do not.

Small sponsors are disproportionately affected

70% of CRLs were issued to small or mid-sized sponsors. Regulatory capacity, CDMO oversight, and CMC program maturity – all of which are resource-intensive – are structural risk factors for organizations without large quality infrastructure.

Real-time CRL disclosure changes competitive intelligence

The September 2025 policy shift means future rejections are visible almost immediately after issuance. For regulatory affairs teams monitoring competitor applications, this creates a new intelligence stream – and for sponsors, it removes the information asymmetry that previously allowed undisclosed failures.

First-cycle approval rates show where preparation matters

74% of 2024 approvals cleared on the first review cycle. First-cycle approval is the outcome of CMC readiness, clean facility inspections, and well-designed clinical programs. The CRL dataset confirms that all three are independently verifiable failure points.

Sources

FDA Sources

Industry and Research Sources